Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer

Authors: Shanshan Liu, Ziwei Ye, Vivian Weiwen Xue, Qi Sun, Huan Li, Desheng Lu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The kinesin-13 family member 2C (KIF2C) is a versatile protein participating in many biological processes. KIF2C is frequently up-regulated in multiple types of cancer and is associated with cancer development. However, the role of KIF2C in immune cell infiltration of tumor microenvironment and immunotherapy in breast cancer remains unclear.

Methods

The expression of KIF2C was analyzed using Tumor Immune Estimation Resource (TIMER) database and further verified by immunohistochemical staining in human breast cancer tissues. The correlation between KIF2C expression and clinical parameters, the impact of KIF2C on clinical prognosis and independent prognostic factors were analyzed by using TCGA database, the Kaplan-Meier plotter, and Univariate and multivariate Cox analyses, respectively. The nomograms were constructed according to independent prognostic factors and validated with C-index, calibration curves, ROC curves, and decision curve analysis. A gene set enrichment analysis (GSEA) was performed to explore the underlying molecular mechanisms of KIF2C. The degree of immune infiltration was assessed by the Estimation of Stromal and Immune cells in Malignant Tumor tissues using the Expression (ESTIMATE) algorithm and the single sample GSEA (ssGSEA). The Tumor mutational burden and Tumor Immune Dysfunction and Rejection (TIDE) were used to analyze immunotherapeutic efficiency. Finally, the KIF2C-related competing endogenous RNA (ceRNA) network was constructed to predict the putative regulatory mechanisms of KIF2C.

Results

KIF2C was remarkably up-regulated in 18 different types of cancers, including breast cancer. Kaplan-Meier survival analysis showed that high KIF2C expression was associated with poor overall survival (OS). KIF2C expression was associated with clinical parameters such as age, TMN stage, T status, and molecular subtypes. We identified age, stage, estrogen receptor (ER) and KIF2C expression as OS-related independent prognosis factors for breast cancer. An OS-related nomogram was developed based on these independent prognosis factors and displayed good predicting ability for OS of breast cancer patients. Finally, our results revealed that KIF2C was significantly related to immune cell infiltration, tumor mutational burden, and immunotherapy in patients with breast cancer.

Conclusion

KIF2C was overexpressed in breast cancer and was positively correlated with immune cell infiltration and immunotherapy response. Therefore, KIF2C can serve as a potential biomarker for prognosis and immunotherapy in breast cancer.
Appendix
Available only for authorised users
Literature
1.
Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.PubMedCrossRef
2.
3.
4.
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.PubMedCrossRef
5.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and targeted Anticancer Agents. Cancer Cell. 2015;28:690–714.PubMedCrossRef
6.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67.PubMedPubMedCentralCrossRef
7.
8.
Valipour B, Velaei K, Abedelahi A, Karimipour M, Darabi M, Charoudeh HN. NK cells: an attractive candidate for cancer therapy. J Cell Physiol. 2019;234:19352–65.PubMedCrossRef
9.
Farhood B, Najafi M, Mortezaee K. CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509–21.PubMedCrossRef
10.
11.
Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully. Biomed Pharmacother. 2020;132:110873.PubMedCrossRef
12.
Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, et al. Current Landscape of Immunotherapy in breast Cancer: a review. JAMA Oncol. 2019;5:1205–14.PubMedPubMedCentralCrossRef
13.
Monnot GC, Romero P. Rationale for immunological approaches to breast cancer therapy. Breast. 2018;37:187–95.PubMedCrossRef
14.
de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, et al. Breast Cancer Immunology and Immunotherapy: current status and future perspectives. Int Rev Cell Mol Biol. 2017;331:1–53.PubMedCrossRef
15.
Hashemi V, Maleki LA, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, et al. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. Int Immunopharmacol. 2020;78:106087.PubMedCrossRef
16.
Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4 + T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635–47.PubMedCrossRef
17.
Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020;20:151–8.PubMedCrossRef
18.
Manning AL, Ganem NJ, Bakhoum SF, Wagenbach M, Wordeman L, Compton DA. The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. Mol Biol Cell. 2007;18:2970–9.PubMedPubMedCentralCrossRef
19.
Zhu S, Paydar M, Wang F, Li Y, Wang L, Barrette B, et al. Kinesin Kif2C in regulation of DNA double strand break dynamics and repair. Elife. 2020;9:e53402.PubMedPubMedCentralCrossRef
20.
21.
Wei S, Dai M, Zhang C, Teng K, Wang F, Li H, et al. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. Protein Cell. 2021;12:788–809.PubMedCrossRef
22.
Ding Q, Jiang C, Zhou Y, Duan J, Lai J, Jiang M, et al. Kinesin family member 2 C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway. Biosci Biotechnol Biochem. 2021;85:2241–9.PubMedCrossRef
23.
Nakamura Y, Tanaka F, Haraguchi N, Mimori K, Matsumoto T, Inoue H, et al. Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer. 2007;97:543–9.PubMedPubMedCentralCrossRef
24.
Ishikawa K, Kamohara Y, Tanaka F, Haraguchi N, Mimori K, Inoue H, et al. Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br J Cancer. 2008;98:1824–9.PubMedPubMedCentralCrossRef
25.
Shimo A, Tanikawa C, Nishidate T, Lin M-L, Matsuda K, Park J-H, et al. Involvement of kinesin family member 2 C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 2008;99:62–70.PubMed
26.
Bie L, Zhao G, Wang Y, Zhang B. Kinesin family member 2 C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin Neurol Neurosurg. 2012;114:356–60.PubMedCrossRef
27.
Moon HH, Kreis N-N, Friemel A, Roth S, Schulte D, Solbach C, et al. Mitotic Centromere-Associated Kinesin (MCAK/KIF2C) regulates Cell Migration and Invasion by modulating Microtubule Dynamics and focal adhesion turnover. Cancers (Basel). 2021;13:5673.PubMedCrossRef
28.
An L, Zhang J, Feng D, Zhao Y, Ouyang W, Shi R, et al. KIF2C is a Novel Prognostic Biomarker and correlated with Immune Infiltration in Endometrial Cancer. Stem Cells Int. 2021;2021:1434856.PubMedPubMedCentralCrossRef
29.
Li T-F, Zeng H-J, Shan Z, Ye R-Y, Cheang T-Y, Zhang Y-J, et al. Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer. Cancer Cell Int. 2020;20:123.PubMedPubMedCentralCrossRef
30.
Cai Y, Mei J, Xiao Z, Xu B, Jiang X, Zhang Y, et al. Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico. Hereditas. 2019;156:20.PubMedPubMedCentralCrossRef
31.
Jayanthi VSPKSA, Das AB, Saxena U. Grade-specific diagnostic and prognostic biomarkers in breast cancer. Genomics. 2020;112:388–96.PubMedCrossRef
32.
Chen G, Yu M, Cao J, Zhao H, Dai Y, Cong Y, et al. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis. Bioengineered. 2021;12:5149–61.PubMedPubMedCentralCrossRef
33.
Fang L, Liu Q, Cui H, Zheng Y, Wu C. Bioinformatics Analysis Highlight differentially expressed CCNB1 and PLK1 genes as potential anti-breast Cancer drug targets and prognostic markers. Genes (Basel). 2022;13:654.PubMedCrossRef
34.
Tu B, Xiang H, Li M, Zhong F, Fang M, Yan W. In Silico Analysis of the correlation of KIF2C with prognosis and Immune Infiltration in Glioma. Comput Math Methods Med. 2022;2022:6320828.PubMedPubMedCentralCrossRef
35.
Huang R, Liu J, Li H, Zheng L, Jin H, Zhang Y, et al. Identification of hub genes and their correlation with Immune Infiltration cells in Hepatocellular Carcinoma based on GEO and TCGA databases. Front Genet. 2021;12:647353.PubMedPubMedCentralCrossRef
36.
Li J, Zhou J, Kai S, Wang C, Wang D, Jiang J. Functional and clinical characterization of Tumor-Infiltrating T cell subpopulations in Hepatocellular Carcinoma. Front Genet. 2020;11:586415.PubMedPubMedCentralCrossRef
37.
Wei Y, Chen X, Ren X, Wang B, Zhang Q, Bu H, et al. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Front Genet. 2021;12:680369.PubMedPubMedCentralCrossRef
38.
Z DW. Y, Y J, L L, Y L, F M, Identification of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis.Scientific reports. 2021;11.
39.
Yin Z, Wu D, Shi J, Wei X, Jin N, Lu X, et al. Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis. BMC Cancer. 2020;20:1062.PubMedPubMedCentralCrossRef
40.
Yu L, Shen H, Ren X, Wang A, Zhu S, Zheng Y, et al. Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis. Sci Rep. 2021;11:11926.PubMedPubMedCentralCrossRef
41.
Liu S, Chen X, Zheng H, Shi S, Li Y. Knockdown of Rab5a expression decreases cancer cell motility and invasion through integrin-mediated signaling pathway. J Biomed Sci. 2011;18:58.PubMedPubMedCentralCrossRef
42.
43.
44.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587–92.PubMedCrossRef
45.
Taniyama T, Holden HT. Cytolytic activity against tumor cells by macrophage cell lines and augmentation by macrophage stimulants. Int J Cancer. 1980;26:61–9.PubMedCrossRef
46.
47.
A P, E P, B A, P G, A F, L G, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer.Breast (Edinburgh, Scotland). 2015;24 Suppl 2.
48.
Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103 + tumor-resident CD8 + T cells are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand significantly during Anti-PD-1 treatment. Clin Cancer Res. 2018;24:3036–45.PubMedCrossRef
49.
Song W-M, Agrawal P, Von Itter R, Fontanals-Cirera B, Wang M, Zhou X, et al. Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis. Nat Commun. 2021;12:1214.PubMedPubMedCentralCrossRef
50.
Becker PSA, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. 2016;65:477–84.PubMedPubMedCentralCrossRef
51.
52.
53.
Ishikawa H, Marshall WF. Ciliogenesis: building the cell’s antenna. Nat Rev Mol Cell Biol. 2011;12:222–34.PubMedCrossRef
54.
55.
56.
Song X, Zhang T, Wang X, Liao X, Han C, Yang C, et al. Distinct diagnostic and prognostic values of Kinesin Family Member genes expression in patients with breast Cancer. Med Sci Monit. 2018;24:9442–64.PubMedPubMedCentralCrossRef
57.
Lucanus AJ, Yip GW. Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics. Oncogene. 2018;37:833–8.PubMedCrossRef
58.
Mackenzie KJ, Carroll P, Martin C-A, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461–5.PubMedPubMedCentralCrossRef
59.
Kwon J, Bakhoum SF. The cytosolic DNA-Sensing cGAS-STING pathway in Cancer. Cancer Discov. 2020;10:26–39.PubMedCrossRef
60.
Kitajima S, Tani T, Springer BF, Campisi M, Osaki T, Haratani K, et al. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer Cell. 2022;40:1128–1144e8.PubMedCrossRef
Metadata
Title
KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer
Authors
Shanshan Liu
Ziwei Ye
Vivian Weiwen Xue
Qi Sun
Huan Li
Desheng Lu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10788-4

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma

Research

Differential presence of exons (DPE): sequencing liquid biopsy by NGS. A new method for clustering colorectal Cancer patients

Research

Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients

Research

Prognostic and immune infiltrative biomarkers of CENPO in pan–cancer and its relationship with lung adenocarcinoma cell proliferation and metastasis

Study Protocol

Protocol for the SEHNeCa randomised clinical trial assesing Supervised Exercise for Head and Neck Cancer patients

Research

Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits